New COPD drug candidate enters early human safety testing

NCT ID NCT06154837

Ongoing Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called GSK3862995B to see if it is safe and tolerable. First, healthy adults receive a single dose, then people with chronic obstructive pulmonary disease (COPD) receive multiple doses. The goal is to check for side effects and how the drug behaves in the body, not yet to prove it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE

Contacts and locations

Locations

GSK Investigational Site

Yuma, Arizona, 85365, United States
GSK Investigational Site

Hialeah, Florida, 33016, United States
GSK Investigational Site

Orange City, Florida, 32763, United States
GSK Investigational Site

Plantation, Florida, 33324, United States
GSK Investigational Site

Columbus, Georgia, 31904, United States
GSK Investigational Site

Shelby, North Carolina, 28150, United States
GSK Investigational Site

Medford, Oregon, 97504, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19107, United States
GSK Investigational Site

Rock Hill, South Carolina, 29732, United States
GSK Investigational Site

Austin, Texas, 78744, United States
GSK Investigational Site

Ahrensburg, 22926, Germany
GSK Investigational Site

Berlin, 10117, Germany
GSK Investigational Site

Berlin, 10119, Germany
GSK Investigational Site

Berlin, 14050, Germany
GSK Investigational Site

Dresden, 01069, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Hamburg, 20253, Germany
GSK Investigational Site

Hamburg, Hamburg, Germany
GSK Investigational Site

Hanover, 30159, Germany
GSK Investigational Site

Immenhausen, 34376, Germany
GSK Investigational Site

Leipzig, 04207, Germany
GSK Investigational Site

Lübeck, 23552, Germany
GSK Investigational Site

Mainz, 55128, Germany
GSK Investigational Site

Schwerin, 19055, Germany
GSK Investigational Site

Barnsley, S75 3DL, United Kingdom
GSK Investigational Site

Blackpool, FY2 0JH, United Kingdom
GSK Investigational Site

Cambridge, CB2 0GG, United Kingdom
GSK Investigational Site

Cannock, WS11 0BN, United Kingdom
GSK Investigational Site

London, HA1 3UJ, United Kingdom
GSK Investigational Site

London, United Kingdom
GSK Investigational Site

Manchester, M23 9QZ, United Kingdom
GSK Investigational Site

West Yorkshire, LS10 1DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.